Jelmyto (Mitomycin) Patent Expiration, LOE Window & CMS Spending

Jelmyto (Mitomycin) by Urogen: FDA Orange Book LOE 2031-01-20, 0 AB generics, $1.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUrogen
FDA Application & PathwayN211728 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-01-20
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.0M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel